09:16 AM EST, 11/03/2026 (MT Newswires) -- Camurus (CAMX.ST) dosed the first patient in the phase 2b trial of CAM2056, its monthly semaglutide subcutaneous depot, for overweight or obese patients. The phase 1b study will evaluate the drug's efficacy and safety in 150 participants, with CAM2056 randomized in doses of 10 milligrams, 20 mg, or placebo, given every four weeks after an initiation period, according to a Tuesday release. The trial's primary objective is to show that the 20-mg dose is superior to placebo in reducing body weight after 36 weeks of treatment. The biopharmaceutical company said results are expected in the first half of 2028.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.